More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Dinaciclib [779353-01-4]

Dinaciclib [779353-01-4]

Research Use Only
D3352
LKT Laboratories
Estimated Purity≥99%
Product group Chemicals
€ 232,00
5 mg
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    LKT Laboratories
  • Product Name
    Dinaciclib [779353-01-4]
  • Delivery Days Customer
    7
  • Certification
    Research Use Only
  • Estimated Purity
    ≥99%
  • Format
    DMSO 26 mg/mL warmed (65.57 mM); Ethanol 8 mg/mL warmed (20.17 mM); Water Insoluble
  • Scientific Description
    BRD binding agent, CDK1/2/5/9 inhibitor.; SCH 727965
  • Storage Instruction
    -20°C
  • UNSPSC
    12352200

References

  • Flynn J, Jones J, Johnson AJ, et al. Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print]. PMID: 25708835. Martin MP, Olesen SH, Georg GI, et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol. 2013 Nov 15;8(11):2360-5. PMID: 24007471. Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. PMID: 23949430. Feldmann G, Mishra A, Bisht S, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. PMID: 21768779.